Zygogen Licenses Antisense Tech from University of Minnesota

Zygogen said this week that it has taken an exclusive license to morpholino antisense technology from the University of Minnesota for use in its zebrafish-based drug-discovery.

Terms of the agreement include license and royalty payments to the University of Minnesota. In addition, Zygogen has the right to sub-license the technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.